The epidemiology of hepatitis C virus in Afghanistan: Systematic review and meta-analysis

International Journal of Infectious Diseases

Volumn 40, Issue , 2015, Pages 54-63

  Chemaitelly, Hiam ^a   Mahmud, Sarwat ^a   Rahmani, Ahmad Masoud ^b   Abu Raddad, Laith J ^a,c  

^a WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^b Afghanistan National Blood Safety and Transfusion Services   (Afghanistan)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Afghanistan; Epidemiology; Hepatitis C virus; Middle East; Prevalence; Systematic review

Indexed keywords

AFGHANISTAN; CONFIDENCE INTERVAL; GENOTYPE; HEMODIALYSIS; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NONHUMAN; POPULATION RISK; PREVALENCE; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; THALASSEMIA; HEPACIVIRUS; META ANALYSIS;

AFGHANISTAN; HEPACIVIRUS; HEPATITIS C; HUMANS; INCIDENCE; PREVALENCE;

EID: 84945250316     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.09.011     Document Type: Review

References (82)

1. Centers for Disease Control and Prevention. Hepatitis C. Atlanta, GA: CDC; 2015.
2. World Health Organization. Hepatitis C: fact sheet. Geneva, Switzerland: WHO; 2015.
3. A Special Meeting Review Edition: advances in the treatment of hepatitis C virus infection from EASL 2014. Gastroenterol Hepatol (N Y) 2014, 10(1 Suppl 1):1-19.
4. WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health-care settings 2015, World Health Organization, WHO, Geneva, Switzerland.
5. Making all injections safe 2015, World Health Organization, WHO, Geneva, Switzerland.
6. Mohamoud Y.A., Mumtaz G.R., Riome S., Miller D., Abu-Raddad L.J. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013, 13:288.
7. El-Zanaty F., Way A. Egypt demographic and health survey 2008 2009, Egyptian Ministry of Health, National Population Council, El-Zanaty and Associates, and ORC Macro, Cairo.
8. Umar M., Bushra H.T., Ahmad M., Data A., Khurram M., Usman S., et al. Hepatitis C in Pakistan: a review of available data. Hepat Mon 2010, 10:205-214.
9. Qureshi H., Bile K.M., Jooma R., Alam S.E., Afridi H.U. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J 2010, 16(Suppl):S15-S23.
10. World drug report 2014, United Nations Office on Drugs and Crime, UNODC.
11. Chaabna K., Mohamoud Y.A., Chemaitelly H., Mumtaz G.R., Abu-Raddad L.J. Protocol for a systematic review and meta-analysis of hepatitis C virus (HCV) prevalence and incidence in the Horn of Africa sub-region of the Middle East and North Africa. Syst Rev 2014, 3:146.
12. Fadlalla F.A., Mohamoud Y.A., Mumtaz G.R., Abu-Raddad L.J. The epidemiology of hepatitis C virus in the Maghreb region: systematic review and meta-analyses. PLoS One 2015, 10:e0121873.
13. Mohamoud YA, Riome S, Abu-Raddad LJ. The epidemiology of hepatitis C virus in the Arabian Gulf countries: systematic review and meta-analyses. Unpublished results.
14. Chemaitelly H., Chaabna K., Abu-Raddad L.J. The epidemiology of hepatitis C virus in the Fertile Crescent: systematic review and meta-analysis. PLoS One 2015, 10:e0135281.
15. Mahmud S, Akbarzadeh V, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Iran: systematic review and meta-analyses. Unpublished results.
16. Chaabna K, Kouyoumjian S, Abu-Raddad LJ. Hepatitis C virus prevalence and incidence in the Horn of Africa sub-region of the Middle East and North Africa: systematic review and meta-analysis. Unpublished results.
17. Chaabna K, Mohamoud YA, Chemaitelly H, Mumtaz GR, Abu-Raddad LJ. Protocol for a systematic review and meta-analysis of hepatitis C virus (HCV) prevalence and incidence in The Horn of Africa sub-region of the Middle East and North Africa. Prospero 2014: CRD42014010318. Available at: (accessed July 10, 2015). http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014010318%202014.
18. Moher D., Liberati A., Tetzlaff J., Altman D.G., Prisma Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.
19. Abu-Raddad L., Akala F.A., Semini I., Riedner G., Wilson D., Tawil O. Characterizing the HIV/AIDS epidemic in the Middle East and North Africa: time for strategic action 2010, The World Bank Press, Washington DC.
20. Abu-Raddad L.J., Hilmi N., Mumtaz G., Benkirane M., Akala F.A., Riedner G., et al. Epidemiology of HIV infection in the Middle East and North Africa. AIDS 2010, 24(Suppl 2):S5-S23.
21. Afghanistan National Blood Safety and Transfusion Services, Central Blood Bank 2015, Ministry of Public Health, Kabul, Afghanistan.
22. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
23. Kuo G., Choo Q.L., Alter H.J., Gitnick G.L., Redeker A.G., Purcell R.H., et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989, 244:362-364.
24. IBM SPSS Statistics for Windows, version 22.0 2013, IBM Corporation, IBM Corporation, Armonk, New York.
25. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011, 17:107-115.
26. Gower E., Estes C., Blach S., Razavi-Shearer K., Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014, 61:S45-S57.
27. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378:571-583.
28. Shannon C.E. The mathematical theory of communication. 1963. MD Comput 1997, 14:306-317.
29. Freeman M.F., Tukey J.W. Transformations related to the angular and the square root. Ann Math Statist 1950, 21:607-611.
30. Borenstein M. Introduction to meta-analysis 2009, John Wiley & Sons, Chichester, UK.
31. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
32. R 3.1.2: a language and environment for statistical computing 2014, R Core Team, R Project, Vienna, Austria.
33. Cochrane handbook for systematic reviews of interventions 2008, The Cochrane Collaboration, Wiley-Blackwell, Hoboken, NJ.
34. Integrated behavioral and biological surveillance (IBBS) in Afghanistan: year 1 report 2010, Afghanistan National AIDS Control Program, HIV Surveillance Project-Johns Hopkins University School of Public Health, National AIDS Control Program, Ministry of Public Health, Kabul, Afghanistan.
35. Integrated behavioral and biological surveillance (IBBS) in selected cities of Afghanistan: findings of 2012 IBBS survey and comparison to 2009 IBBS survey 2012, Afghanistan National AIDS Control Program, Johns Hopkins University School of Public Health, National AIDS Control Program, Ministry of Public Health, Kabul, Afghanistan.
36. UNGASS country progress report 2010: Islamic Republic of Afghanistan 2010, Afghanistan National AIDS Control Program, Ministry of Public Health, Director General of Preventive Medicine and Primary Health Care, Communicable Disease Directorate (CDC), Islamic Republic of Afghanistan.
37. Khan S., Attaullah S. Share of Afghanistan populace in hepatitis B and hepatitis C infection's pool: is it worthwhile?. Virol J 2011, 8:216.
38. Report of testing of blood donors from March-December, 2006 2006, Central Blood Bank, Ministry of Public Health, Kabul, Afghanistan.
39. Ayyoubi M.T., Konstenius T., McCullough J.C., Eastlund T., Clay M., Bowman R., et al. Status of blood banking and the blood supply in Afghanistan. Transfusion 2010, 50:566-574.
40. Mansoor G.F., Rahmani A.M., Kakar M.A., Hashimy P., Abrahimi P., Scott P.T., et al. Blood supply safety in Afghanistan: a national assessment of high-volume facilities. Transfusion 2013, 53:2061-2068.
41. Dupire B., Abawi A.K., Ganteaume C., Lam T., Truze P., Martet G. [Establishment of a blood transfusion center at Kabul (Afghanistan)]. Sante 1999, 9:18-22.
42. Ruisenor-Escudero H., Wirtz A.L., Berry M., Mfochive-Njindan I., Paikan F., Yousufi H.A., et al. Risky behavior and correlates of HIV and hepatitis C virus infection among people who inject drugs in three cities in Afghanistan. Drug Alcohol Depend 2014, 143:127-133.
43. Todd C.S., Nasir A., Stanekzai M.R., Rasuli M.Z., Fiekert K., Orr M., et al. Hepatitis C and HIV incidence among injecting drug users in Kabul, Afghanistan. Abstract MOPDC101. XVIII International AIDS Conference 2010.
44. Pehlivanoglu F., Yasar K.K., Sengoz G. Asylum seekers: do we need new approaches to their health problems? (In Turkish) Siginmacilar: Saglik problemleri icin yeni yaklasimlara ihtiyac var mi. Nobel Medicus 2011, 7:102-105.
45. Richter C., Beest G.T., Gisolf E.H., Van Bentum P., Waegemaekers C., Swanink C., et al. Screening for chronic hepatitis B and C in migrants from Afghanistan, Iran, Iraq, the former Soviet Republics, and Vietnam in the Arnhem region, the Netherlands. Epidemiol Infect 2014, 142:2140-2146.
46. Tanju I.A., Levent F., Sezer R.G., Cekmez F. Hepatitis B, hepatitis C and human immunodeficiency virus seropositivity among children in Kabul, Afghanistan: a cross-sectional study. Hepat Mon 2014, 14:e16154.
47. th International AIDS Conference 2012.
48. Todd C.S., Ahmadzai M., Atiqzai F., Miller S., Smith J.M., Ghazanfar S.A., et al. Seroprevalence and correlates of HIV, syphilis, and hepatitis B and C virus among intrapartum patients in Kabul, Afghanistan. BMC Infect Dis 2008, 8:119.
49. Nasir A., Todd C.S., Stanekzai M.R., Bautista C.T., Botros B.A., Scott P.T., et al. Prevalence of HIV, hepatitis B and hepatitis C and associated risk behaviours amongst injecting drug users in three Afghan cities. Int J Drug Policy 2011, 22:145-152.
50. Todd C.S., Nasir A., Stanekzai M.R., Fiekert K., Rasuli M.Z., Vlahov D., et al. Prevalence and correlates of HIV, syphilis, and hepatitis B and C infection and harm reduction program use among male injecting drug users in Kabul, Afghanistan: a cross-sectional assessment. Harm Reduct J 2011, 8:22.
51. Todd C.S., Abed A.M., Strathdee S.A., Scott P.T., Botros B.A., Safi N., et al. HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan. Emerg Infect Dis 2007, 13:1327-1331.
52. Nasir A., Todd C.S., Stanekzai M.R., Bautista C.T., Botros B.A., Scott P.T., et al. Implications of hepatitis C viremia vs. antibody alone on transmission among male injecting drug users in three Afghan cities. Int J Infect Dis 2011, 15:e201-e205.
53. Todd C.S., Nasir A., Stanekzai M.R., Bautista C.T., Botros B.A., Scott P.T., et al. HIV, hepatitis B, and hepatitis C prevalence and associated risk behaviors among female sex workers in three Afghan cities. AIDS 2010, 24(Suppl 2):S69-S75.
54. Vahdani P., Hosseini-Moghaddam S.M., Gachkar L., Sharafi K. Prevalence of hepatitis B, hepatitis C, human immunodeficiency virus, and syphilis among street children residing in southern Tehran, Iran. Arch Iran Med 2006, 9:153-155.
55. Sanders-Buell E., Rutvisuttinunt W., Todd C.S., Nasir A., Bradfield A., Lei E., et al. Hepatitis C genotype distribution and homology among geographically disparate injecting drug users in Afghanistan. J Med Virol 2013, 85:1170-1179.
56. Bautista C.T., Todd C.S., Abed A.M., Botros B.A., Strathdee S.A., Earhart K.C., et al. Effects of duration of injection drug use and age at first injection on HCV among IDU in Kabul, Afghanistan. J Public Health (Oxf) 2010, 32:336-341.
57. Mohd Hanafiah K., Groeger J., Flaxman A.D., Wiersma S.T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57:1333-1342.
58. Cornberg M., Razavi H.A., Alberti A., Bernasconi E., Buti M., Cooper C., et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011, 31(Suppl 2):30-60.
59. Prevalence of hepatitis B and C in Pakistan 2008, Pakistan Medical Research Council, Pakistan Medical Research Council, Islamabad, Afghanistan.
60. Zou S., Dorsey K.A., Notari E.P., Foster G.A., Krysztof D.E., Musavi F., et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010, 50:1495-1504.
61. Denniston M.M., Jiles R.B., Drobeniuc J., Klevens R.M., Ward J.W., McQuillan G.M., et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014, 160:293-300.
62. Alter M.J. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007, 13:2436-2441.
63. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
64. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
65. Mumtaz G.R., Weiss H.A., Thomas S.L., Riome S., Setayesh H., Riedner G., et al. HIV among people who inject drugs in the Middle East and North Africa: systematic review and data synthesis. PLoS Med 2014, 11:e1001663.
66. Drug use in Afghanistan: 2009 survey-executive summary 2010, United Nations Office on Drugs and Crime, UNODC Afghanistan Office, Kabul, Afghanistan.
67. Mumtaz G.R., Weiss H.A., Abu-Raddad L.J. Hepatitis C virus and HIV infections among people who inject drugs in the Middle East and North Africa: a neglected public health burden?. J Int AIDS Soc 2015, 18:20582.
68. Todd C.S., Macdonald D., Khoshnood K., Mansoor G.F., Eggerman M., Panter-Brick C. Opiate use, treatment, and harm reduction in Afghanistan: recent changes and future directions. Int J Drug Policy 2012, 23:341-345.
69. Micallef J.M., Macdonald V., Jauncey M., Amin J., Rawlinson W., van Beek I., et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 2007, 14:413-418.
70. Todd C.S., Abed A.M., Scott P.T., Safi N., Earhart K.C., Strathdee S.A. A cross-sectional assessment of utilization of addiction treatment among injection drug users in Kabul, Afghanistan. Subst Use Misuse 2009, 44:416-430.
71. Mumtaz G.R., Weiss H., Vickerman P., Larke N., Abu-Raddad L.J. Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa. AIDS 2015, 29:1701-1710.
72. Cainelli F. Hepatitis C virus and human immunodeficiency virus transmission routes: differences and similarities. World J Hepatol 2013, 5:234-236.
73. Terrault N.A., Dodge J.L., Murphy E.L., Tavis J.E., Kiss A., Levin T.R., et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology 2013, 57:881-889.
74. Klevens R.M., Hu D.J., Jiles R., Holmberg S.D. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis 2012, 55(Suppl 1):S3-S9.
75. Wong J., Moore D., Kanters S., Buxton J., Robert W., Gustafson R., et al. Seroprevalence of hepatitis C and correlates of seropositivity among men who have sex with men in Vancouver, Canada: a cross-sectional survey. Sex Transm Infect 2015, 91:430-433. ManCount Study Team.
76. Sievert W., Altraif I., Razavi H.A., Abdo A., Ahmed E.A., Alomair A., et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011, 31(Suppl 2):61-80.
77. Messina J.P., Humphreys I., Flaxman A., Brown A., Cooke G.S., Pybus O.G., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015, 61:77-87.
78. Cuadros D.F., Branscum A.J., Miller F.D., Abu-Raddad L.J. Spatial epidemiology of hepatitis C virus infection in Egypt: analyses and implications. Hepatology 2014, 60:1150-1159.
79. Miller F.D., Abu-Raddad L.J. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci U S A 2010, 107:14757-14762.
80. Chemaitelly H., Abu-Raddad L.J., Miller F.D. An apparent lack of epidemiologic association between hepatitis C virus knowledge and the prevalence of hepatitis C infection in a national survey in Egypt. PLoS One 2013, 8:e69803.
81. Benova L., Awad S.F., Miller F.D., Abu-Raddad L.J. Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt. Hepatology 2015, 61:834-842.
82. Guerra J., Garenne M., Mohamed M.K., Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 2012, 19:560-567.